leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PHARMA REPORT

rss_Pharma.jpg...see all
Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022

Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022

  • Publication date: 26/03/2012
  • Number of Pages: 223
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

Generic drugs - discover potentials and revenue prospects of companies, seeing what the future holds

How are companies in the generics market performing? Visiongain's report gives you data, analyses and discussions for leading manufacturers of generic drugs.

That new study lets you assess prominent companies in the generics market from 2012 to 2022. See how companies worldwide are performing and where they are heading.

There, you find analytical profiles for leading producers - activities, outlooks and prospects:
• Teva Pharmaceutical Industries
• Sandoz
• Mylan
• Actavis
• Hospira
• Watson
• Abbott
• Sanofi
• Ranbaxy
• Cipla
• Aspen
• Stada Arzneimittel
• Coverage of 38 other leading companies from around the world.

See how generics manufacturers compare, finding out how they can compete from 2012.

Our investigation gives you business research and analysis, including revenue forecasts to 2022. You discover commercial data, predictions and discussions for companies and the market in which they operate.

Where is the generics market heading? Many opportunities exist, especially in Japan and developing countries. Generic substitution is rising in Europe and the US.

Also, which producers will expand beyond their domestic and regional markets to become global forces for the manufacturing and sales of generic drugs? As our study shows, there are many companies breaking into new markets and expanding generic product ranges.

Complex generics, with high market entry barriers, and biosimilar (follow-on biologic/protein) products will transform the generics industry and pharma markets. Many opportunities exist for drug companies with biotechnological capabilities. Our report shows and explains.

The patent cliff will result in many more of the pharmaceutical industry's blockbusters being opened to generic competition. Which generic drug producers can best seize opportunities from 2012 to 2022? You find answers now in our study.

Company analysis, revenue forecasts and discussions of industry prospects

In Visiongain's report you find historical revenues, sales predictions, growth rates and market breakdowns. Also, you see discussions of companies, product portfolios and growth potential. You receive 215 tables and charts.

Ten ways Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:
• Assess 50 leading generics producers, discovering their activities and outlooks
• Discover market leaders in each region
• Receive analyses of leading companies, seeing revenue forecasts to 2022
• View a comparative analysis of generics players
• Assess commercial prospects, market breakdowns and product offerings
• Find existing revenues and operational data for leading companies
• Review technological, regulatory and commercial developments, assessing trends and prospects
• Analyse prospects for generic drug launches
• Investigate competition and opportunities influencing revenues
• Find out what will stimulate and restrain the industry and market.

There, you find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Gain business research and analysis on generic drug makers now

Our study is for everybody needing industry and market analyses for generic drug companies. You find data, trends and answers there. Please order that report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6 

Table of Contents

1. Executive Summary
1.1 Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report
1.5 Overview: Top 50 Generic Drug Manufacturers

2. The Leading Generic Drug Manufacturer: Teva Pharmaceutical Industries, 2012-2022
2.1 Teva's Generics Business, 2012
2.2 Regional Sales for Teva Generics, 2010-2011
2.3 Teva's M&A Strategy, 2012
2.4 Growth Forecast for Teva, 2012-2022

3. The Leading Big Pharma Generic Drug Manufacturers, 2012-2022
3.1 Novartis (Sandoz), 2012
3.1.1 Novartis' Generics Business, 2012
3.1.2 Sales Breakdown for Novartis Generics, 2010-2011
3.1.3 Growth Strategy for Novartis Generics, 2012-2022
3.1.4 Growth Forecast for Novartis Generics, 2012-2022
3.2 Abbott Laboratories, 2012
3.2.1 Abbott's Generics Business, 2012
3.2.2 Abbott's Position in the Emerging Markets, 2012
3.2.3 Growth Forecast for Abbott Generics, 2012-2022
3.3 Pfizer, 2012
3.3.1 Pfizer's Generics Business, 2012
3.3.2 Pfizer's Generics Growth Strategy, 2012
3.3.3 Growth Forecast for Pfizer Generics, 2012-2022
3.4 Sanofi, 2012
3.4.1 Sanofi's Generics Business, 2012
3.4.2 Sanofi's Generics Growth Strategy, 2012
3.4.3 Growth Forecast for Sanofi Generics, 2012-2022
3.5 Takeda, 2012
3.5.1 Business Segments of Nycomed, 2011

4. The Leading North American Generic Drug Manufacturers, 2012-2022
4.1 Mylan, 2012
4.1.1 Mylan's Generics Business, 2012
4.1.2 Mylan's Regional Presence, 2012
4.1.3 Growth Forecast for Mylan Generics, 2012-2022
4.2 Hospira, 2012
4.2.1 Hospira's Generics Business, 2012
4.2.2 Hospira Growth Strategies, 2012
4.2.3 Growth Forecast for Hospira Generics, 2012-2022
4.3 Watson Pharmaceuticals, 2012
4.3.1 Watson's Generics Business, 2012
4.3.2 Watson's Growth Strategies, 2012
4.3.3 Growth Forecast for Watson Generics, 2012-2022
4.4 Par Pharmaceutical, 2012
4.4.1 Par's Generics Business, 2012
4.4.2 Par's Growth Strategy, 2012
4.4.3 Litigation Involving Par to 2012
4.5 Apotex, 2012
4.5.1 Apotex's Generics Business, 2012
4.5.2 Apotex in the Canadian Generics Market, 2012
4.5.3 Key Apotex Generic Launches, 2011
4.6 Impax Laboratories, 2012
4.6.1 Impax's Generics Business, 2012
4.7 Covidien (Mallinckrodt), 2012
4.7.1 Mallinckrodt Generics, 2012
4.7.2 Litigation Involving Mallinckrodt
4.8 Pharmascience, 2012
4.8.1 Pharmascience's Generics Business, 2012
4.8.2 Pharmascience's Growth Strategies, 2012
4.9 Perrigo Company, 2012
4.9.1 Perrigo's Generics Business, 2012
4.9.2 Growth Prospects for Perrigo's Generics Business, 2012
4.10 Hi-Tech Pharmacal, 2012
4.10.1 Hi-Tech's Generics Business, 2012
4.10.2 Growth Prospects for Hi-Tech, 2012
4.11 Other North American Generics Companies, 2012

5. The Leading European Generic Drug Manufacturers, 2012-2022
5.1 Actavis, 2012
5.1.1 Actavis' Generics Business, 2012
5.1.2 Actavis' Generics Growth Strategy, 2012
5.1.3 Growth Forecast for Actavis Generics, 2012-2022
5.2 Fresenius Kabi, 2012
5.2.1 Fresenius Kabi's Generics Business, 2012
5.2.2 Growth Strategies for Fresenius Kabi, 2012
5.2.3 Growth Forecast for Fresenius Kabi Generics, 2012-2022
5.3 Stada Arzneimittel, 2012
5.3.1 Stada's Generics Business, 2012
5.3.2 Stada's Growth Prospects, 2012
5.3.3 Growth Forecast for Stada Arzneimittel Generics, 2012-2022
5.4 Gedeon Richter, 2012
5.4.1 Gedeon Richter's Generics Business, 2012
5.4.2 Regional Presence of Gedeon Richter, 2012
5.4.3 Growth Forecast for Gedeon Richter Generics, 2012-2022
5.5 Krka, 2012
5.5.1 Krka's Generics Business, 2012
5.5.2 Krka's Business Growth, 2012
5.5.3 Growth Forecast for Krka Generics, 2012-2022
5.6 Alapis, 2012
5.6.1 Alapis' Generics Business, 2012
5.6.2 Alapis and the Greek Economic Crisis, 2009-2012
5.7 Pharmstandard, 2012
5.7.1 Pharmstandard's Generics Business, 2012
5.7.2 Pharmstandard's Growth Prospects, 2012
5.8 Egis Pharmaceuticals, 2012
5.8.1 Egis' Generics Business, 2012
5.8.2 Egis' Business Strategy, 2012
5.9 Angelini, 2012
5.9.1 Angelini's Generics Business, 2012
5.10 Orion, 2012
5.10.1 Orion's Generics Business, 2012
5.10.2 Orion's Regional Strategy, 2012
5.11 Bilim Pharmaceuticals, 2012
5.11.1 Bilim's Generics Business, 2012
5.11.2 Growth Prospects for Bilim
5.12 Veropharm, 2012
5.12.1 Growth Prospects for Veropharm's Generics Business, 2012
5.13 Elpen Pharmaceutical, 2012
5.13.1 Elpen's Generics Business, 2012
5.14 Eastpharma, 2012
5.14.1 Eastpharma's Generics Business, 2012
5.15 Other European Generics Companies, 2012

6. The Leading Indian Generic Drug Manufacturers, 2012-2022
6.1 Ranbaxy Laboratories, 2012
6.1.1 Ranbaxy's Generics Business, 2012
6.1.2 Ranbaxy's Growth Ambitions, 2012
6.1.3 Growth Forecast for Ranbaxy Generics, 2012-2022
6.2 Cipla, 2012
6.2.1 Cipla's Generics Business, 2012
6.2.2 Cipla and Patent Controversies, 2012
6.2.3 Growth Forecast for Cipla Generics, 2012-2022
6.3 Dr. Reddy's Laboratories, 2012
6.3.1 Dr. Reddy's Generics Business, 2012
6.3.2 Dr. Reddy's Regional Focus, 2012
6.3.3 Growth Forecast for Dr. Reddy's Generics, 2012-2022
6.4 Sun Pharma, 2012
6.4.1 Sun's Generics Business, 2012
6.4.2 Sun's Exports, 2012
6.4.3 Growth Forecast for Sun Pharma Generics, 2012-2022
6.5 Lupin, 2012
6.5.1 Lupin's Generics Business, 2012
6.5.2 Lupin's Regional Expansion, 2012
6.5.3 Growth Forecast for Lupin Generics, 2012-2022
6.6 Wockhardt, 2012
6.6.1 Wockhardt's Generics Business, 2012
6.7 Aurobindo, 2012
6.7.1 Aurobindo's Generics Business, 2012
6.8 Zydus Cadila, 2012
6.8.1 Zydus Cadila's Generics Business, 2012
6.9 Biocon, 2012
6.9.1 Biocon's Generics Business, 2012
6.9.2 Biocon's Collaborations, 2012
6.10 Strides Arcolab, 2012
6.10.1 Strides' Generics Business, 2012
6.10.2 Strides' Business Partnerships, 2012
6.11 Glenmark Pharmaceutical, 2012
6.11.1 Glenmark's Generics Business, 2012
6.11.2 Future Business Direction for Glenmark, 2012
6.12 Other Indian Generics Manufacturers, 2012

7. The Leading Generic Drug Manufacturers in the Rest of the World, 2012-2022
7.1 Aspen Pharma, 2012
7.1.1 Aspen's Generics Business, 2012
7.1.2 Aspen's Regional Presence, 2012
7.1.3 Growth Forecast for Aspen Pharma Generics, 2012-2022
7.2 Hikma Pharmaceuticals, 2012
7.2.1 Hikma's Generics Business and Growth Prospects, 2012
7.3 Sawai Pharmaceutical, 2012
7.3.1 Sawai's Generics Business and Prospects, 2012
7.4 Nichi-Iko Pharmaceutical Co., 2012
7.4.1 Nichi-Iko's Generic Business and Prospects, 2012
7.5 Towa Pharmaceutical, 2012
7.5.1 Towa's Generics Business and Prospects, 2012
7.6 Nippon Chemiphar, 2012
7.6.1 Chemiphar's Generics Business and Prospects, 2012
7.7 LG Life Sciences, 2012
7.7.1 LG Life Sciences' Generics Business and Prospects, 2012
7.8 EMS Sigma, 2012
7.8.1 EMS Sigma's Generics Business and Prospects, 2012
7.9 Eurofarma, 2012
7.9.1 Eurofarma's Generics Business and Prospects, 2012

List of Tables
Table 1.1 Top 50 Generic Pharmaceutical Manufacturers: Revenues ($m) and Ranking, 2010
Table 2.1 Teva Pharmaceutical Industries: Overview, 2010
Table 2.2 Top Ten Generics Sector M&A Deals (Teva Deals Highlighted), 2004-Q1 2012
Table 2.3 Teva Pharmaceutical Industries: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 2.4 Teva Pharmaceutical Industries: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 3.1 Novartis: Overview, 2010
Table 3.2 Novartis: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 3.3 Novartis: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 3.4 Abbott Laboratories: Overview, 2010
Table 3.5 Abbott: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 3.6 Abbott: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 3.7 Pfizer: Overview, 2010
Table 3.8 Pfizer: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 3.9 Pfizer: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 3.10 Sanofi: Overview, 2010
Table 3.11 Sanofi: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 3.12 Sanofi: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 3.13 Takeda: Overview, 2010
Table 4.1 Mylan: Overview, 2010
Table 4.2 Mylan: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 4.3 Mylan: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 4.4 Hospira: Overview, 2010
Table 4.5 Hospira: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 4.6 Hospira: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 4.7 Watson: Overview, 2010
Table 4.8 Some Key Watson Generic Products, 2012
Table 4.9 Watson: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 4.10 Watson: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 4.11 Par Pharmaceutical: Overview, 2010
Table 4.12 Apotex: Overview, 2010
Table 4.13 Impax Laboratories: Overview, 2010
Table 4.14 Covidien: Overview, 2010
Table 4.15 Mallinckrodt Covidien Speciality Generics: Some Key Product Families, 2012
Table 4.16 Pharmascience: Overview, 2010
Table 4.17 Pharmascience Product Dossiers Registered in One or More EU State, 2012
Table 4.18 Perrigo Company: Overview, 2010
Table 4.19 High-Tech Pharmacal: Overview, 2010
Table 4.20 Selected Other North American Generic Companies, 2012
Table 5.1 Actavis: Overview, 2010
Table 5.2 Actavis: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 5.3 Actavis: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 5.4 Fresenius Kabi: Overview, 2010
Table 5.5 Fresenius Kabi: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 5.6 Fresenius Kabi: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 5.7 Stada Arzneimittel: Overview, 2010
Table 5.8 Stada: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 5.9 Stada: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 5.10 Gedeon Richter: Overview, 2010
Table 5.11 Gedeon Richter: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 5.12 Gedeon Richter: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 5.13 Krka: Overview, 2010
Table 5.14 Krka: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 5.15 Krka: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 5.16 Alapis: Overview, 2010
Table 5.17 Pharmstandard: Overview, 2010
Table 5.18 Egis: Overview, 2010
Table 5.19 Angelini: Overview, 2010
Table 5.20 Italian Drug Reimbursement Classes, 2012
Table 5.21 Orion: Overview, 2010
Table 5.22 Bilim Pharmaceuticals: Overview, 2010
Table 5.23 Veropharm: Overview, 2010
Table 5.24 Elpen Pharmaceutical: Overview, 2010
Table 5.25 Leading Elpen Generics, 2011
Table 5.26 EastPharma Pharmaceutical: Overview, 2010
Table 5.27 Leading EastPharma Generics, 2011
Table 5.28 Selected Other European Generics Companies, 2012
Table 6.1 Ranbaxy: Overview, 2010
Table 6.2 Ranbaxy: Top 10 Products, 2010
Table 6.3 Ranbaxy: Top 10 Therapeutic Areas, 2010
Table 6.4 Ranbaxy: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 6.5 Ranbaxy: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 6.6 Cipla: Overview, 2010
Table 6.7 Cipla: Subsidiaries and Affiliates, 2010
Table 6.8 Cipla: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 6.9 Cipla: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 6.10 Dr. Reddy's: Overview, 2010
Table 6.11 Dr. Reddy's: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 6.12 Dr. Reddy's: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 6.13 Sun Pharma: Overview, 2010
Table 6.14 Sun Pharma: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 6.15 Sun Pharma: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 6.16 Lupin: Overview, 2010
Table 6.17 Lupin: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 6.18 Lupin: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 6.19 Wockhardt: Overview, 2010
Table 6.20 Aurobindo: Overview, 2010
Table 6.21 Zydus Cadila: Overview, 2010
Table 6.22 Biocon: Overview, 2010
Table 6.23 Strides Arcolab: Overview, 2010
Table 6.24 Glenmark: Overview, 2010
Table 7.1 Aspen Pharma: Overview, 2010
Table 7.2 Aspen: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 7.3 Aspen: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022
Table 7.4 Hikma: Overview, 2010
Table 7.5 Sawai: Overview, 2010
Table 7.6 Nichi-Iko: Overview, 2010
Table 7.7 Towa: Overview, 2010
Table 7.8 Nippon Chemiphar: Overview, 2010
Table 7.9 LG Life Sciences: Overview, 2010
Table 7.10 EMS Sigma: Overview, 2010
Table 7.11 Eurofarma: Overview, 2010

List of Figures
Figure 2.1 Teva Pharmaceutical Industries: Business Segments Revenue Breakdown (%), 2010
Figure 2.2 Teva Pharmaceutical Industries: Generic Sales ($m), Regional Breakdown, 2011
Figure 2.3 Teva Pharmaceutical Industries: Generic Sales ($m), Quarterly Breakdown, 2011
Figure 2.4 Teva Pharmaceutical Industries: Generic Revenues ($m), 2010-2015
Figure 2.5 Teva Pharmaceutical Industries: Generic Revenues ($m), 2016-2022
Figure 3.1 Novartis: Business Segments Revenue Breakdown (%), 2011
Figure 3.2 Novartis: Generic Revenue Breakdown (%), 2011
Figure 3.3 Novartis: Generic Revenues ($m), 2010-2015
Figure 3.4 Novartis: Generic Revenues ($m), 2016-2022
Figure 3.5 Abbott: Business Segments Revenue Breakdown (%), 2010
Figure 3.6 Abbott: Generic Revenues ($m), 2010-2015
Figure 3.7 Abbott: Generic Revenues ($m), 2016-2022
Figure 3.8 Pfizer: Business Segments Revenue Breakdown (%), 2010
Figure 3.9 Pfizer: Generic Revenues ($m), 2010-2015
Figure 3.10 Pfizer: Generic Revenues ($m), 2016-2022
Figure 3.11 Sanofi: Pharmaceutical Business Segments Revenue Breakdown (%), 2010
Figure 3.12 Sanofi: Generic Revenues ($m), 2010-2015
Figure 3.13 Sanofi: Generic Revenues ($m), 2016-2022
Figure 4.1 Mylan: Revenue Breakdown by Therapeutic Area (%), 2011
Figure 4.2 Mylan: Revenue Breakdown by Business Segment (%), 2011
Figure 4.3 Mylan: Generic Revenues ($m), 2010-2015
Figure 4.4 Mylan: Generic Revenues ($m), 2016-2022
Figure 4.5 Hospira: Revenue Breakdown by Business Segment (%), 2010
Figure 4.6 Hospira: Specialty Injectables Revenue Breakdown by Region (%), 2010
Figure 4.7 Hospira: Generic Revenues ($m), 2010-2015
Figure 4.8 Hospira: Generic Revenues ($m), 2016-2022
Figure 4.9 Watson: Revenue Breakdown by Business Segment (%), 2010
Figure 4.10 Watson: Generic Revenues ($m), 2010-2015
Figure 4.11 Watson: Generic Revenues ($m), 2016-2022
Figure 4.12 Par Generics: Revenue Breakdown by Customer (%), 2010
Figure 4.13 Generic Share in Canadian Market by Revenue (%), 2010
Figure 4.14 Generic Share in Canadian Market by Prescription Volume (%), 2005-2010
Figure 4.15 Impax Sales Channel Revenue Breakdown (%), 2010
Figure 4.16 Impax Generics: Revenue Breakdown by Customer (%), 2010
Figure 4.17 Perrigo Company: Revenue Breakdown by Business Segment (%), 2011
Figure 4.18 Hi-Tech Pharmacal: Revenue Breakdown by Business Segment (%), 2010
Figure 5.1 Actavis: Generic Revenues ($m), 2010-2015
Figure 5.2 Actavis: Generic Revenues ($m), 2016-2022
Figure 5.3 Fresenius SE: Revenue Breakdown by Company (%), 2011
Figure 5.4 Fresenius Kabi: Revenue Breakdown by Business Segment (%), 2010
Figure 5.5 Fresenius Kabi: Revenue Breakdown by Region (%), 2011
Figure 5.6 Fresenius Kabi: Generic Revenues ($m), 2010-2015
Figure 5.7 Fresenius Kabi: Generic Revenues ($m), 2016-2022
Figure 5.8 Stada: Revenue Breakdown by Business Segment (%), 2010
Figure 5.9 Stada: Distribution of Costs (%), 2010
Figure 5.10 Stada: Revenue Breakdown by Region (%), 2010
Figure 5.11 Stada: Generic Revenues ($m), 2010-2015
Figure 5.12 Stada: Generic Revenues ($m), 2016-2022
Figure 5.13 Gedeon Richter: Ownership of the Company (%), 2012
Figure 5.14 Gedeon Richter: Revenue Breakdown by Business Segment, 2010
Figure 5.15 Gedeon Richter: Revenue Breakdown by Therapeutic Area, 2010
Figure 5.16 Gedeon Richter: Revenue Breakdown by Region, 2010
Figure 5.17 Gedeon Richter: Generic Revenues ($m), 2010-2015
Figure 5.18 Gedeon Richter: Generic Revenues ($m), 2016-2022
Figure 5.19 Krka: Revenue Breakdown by Business Segment, 2011
Figure 5.20 Krka: Revenue Breakdown by Region, 2010
Figure 5.21 Krka: Revenue Breakdown by Therapeutic Area, 2010
Figure 5.22 Krka: Generic Revenues ($m), 2010-2015
Figure 5.23 Krka: Generic Revenues ($m), 2016-2022
Figure 5.24 Russian Pharmaceutical Market: Segmentation (%), 2010
Figure 5.25 Leading Companies in the Russian Pharmaceutical Market: Market Share (%), 2010
Figure 5.26 Egis: Revenue Breakdown by Therapeutic Class, FY 2011
Figure 5.27 Egis: Revenue Breakdown by Region, FY 2011
Figure 5.28 Orion: Revenue Breakdown by Business Segment, 2011
Figure 5.29 Orion: Revenue Breakdown by Region, 2011
Figure 5.30 Turkish Pharmaceutical Market: Generic and Originator Products Share of Market by Volume (%), 2010
Figure 5.31 Turkish Pharmaceutical Market: Generic and Originator Products Share of Market by Revenue (%), 2010
Figure 5.32 Veropharm: Leading Prescription Drugs, Company Revenue Share (%), H1 2011
Figure 5.33 Veropharm: Traditional Products, Company Revenue Share (%), H1 2011
Figure 5.34 Veropharm: OTC Products, Company Revenue Share (%), H1 2011
Figure 5.35 Russia's Hospital Oncology Market: Leading Companies by Share (%), H1 2011
Figure 6.1 Ranbaxy: Revenue Breakdown by Region (%), 2010
Figure 6.2 Ranbaxy: Approvals and Filings by Region, 2010
Figure 6.3 Ranbaxy: Generic Revenues ($m), 2010-2015
Figure 6.4 Ranbaxy: Generic Revenues ($m), 2016-2022
Figure 6.5 Cipla: Export Revenues Breakdown by Region (%), 2010
Figure 6.6 Cipla: Generic Revenues ($m), 2010-2015
Figure 6.7 Cipla: Generic Revenues ($m), 2016-2022
Figure 6.8 Dr. Reddy's: Revenue Breakdown by Business Segment (%), 2010
Figure 6.9 Dr. Reddy's: Top Indian Generics Brands, Revenue Share (%) 2010
Figure 6.10 Dr. Reddy's: Revenue Breakdown by Region (%), 2010
Figure 6.11 Dr. Reddy's: Generic Revenues ($m), 2010-2015
Figure 6.12 Dr. Reddy's: Generic Revenues ($m), 2016-2022
Figure 6.13 Sun Pharma: Revenue Breakdown (%) by Business Segment, 2010
Figure 6.14 Sun Pharma: Indian Generics Revenue Breakdown (%) by Therapeutic Area, 2010
Figure 6.15 Sun Pharma: Cumulative ANDA Filings and Approvals, 2004-2011
Figure 6.16 Sun Pharma: Generic Revenues ($m), 2010-2015
Figure 6.17 Sun Pharma: Generic Revenues ($m), 2016-2022
Figure 6.18 Lupin: Breakdown by Business Segment, 2010
Figure 6.19 Lupin: Business Segment Share of Revenues (%), Lupin FY 2007-2011
Figure 6.20 Lupin: Export Markets Share of Revenues (%), Lupin FY 2007-2011
Figure 6.21 Lupin: Generic Revenues ($m), 2010-2015
Figure 6.22 Lupin: Generic Revenues ($m), 2016-2022
Figure 6.23 Wockhardt: Generic Revenues Breakdown by Region (%), 2010
Figure 6.24 Aurobindo: Generic Revenues Breakdown by Region (%), 2010
Figure 6.25 Aurobindo: Generic Drug Submissions and Approvals, Breakdown by Region (%), 2010
Figure 6.26 Zydus Cadila: Generic Revenues Breakdown by Region (%), 2010
Figure 6.27 Biocon: Revenue Breakdown by Business Segment, 2010
Figure 6.28 Strides Arcolab: ANDA Submissions and Approvals, Company FY 2005-2010
Figure 6.29 Glenmark: Revenue Breakdown by Business Segment (%), 2010
Figure 6.30 Glenmark: Generic Revenue Breakdown by Segment (%), 2010
Figure 7.1 Aspen Revenues Breakdown by Region (%), 2011
Figure 7.2 Aspen Revenue Growth by Region (%), 2011
Figure 7.3 South African Market by Company Share (%), June 2011
Figure 7.4 Aspen's Latin American Revenues: Breakdown by Country (%), June 2011
Figure 7.5 Aspen: Generic Revenues ($m), 2010-2015
Figure 7.6 Aspen: Generic Revenues ($m), 2016-2022
Figure 7.7 Hikma: Revenue Breakdown by Business Segment, 2010
Figure 7.8 Hikma: Revenue Breakdown by Region, 2010
Figure 7.9 Sawai: Revenue Breakdown by Therapeutic Class, 2010
Figure 7.10 Sawai: Revenue Breakdown by Sales Channel, 2010
Figure 7.11 Nichi-Iko Generic Portfolio: Breakdown by Formulation, 2010
Figure 7.12 Nichi-Iko AGR (%), Company FY 2001-2010
Figure 7.13 Towa Revenue Breakdown by Therapeutic Class (%), FY 2010
Figure 7.14 Nippon Chemiphar Generic Revenues as Share of Overall Revenues, Company FY 2007-2010
Figure 7.15 Brazilian Pharmaceutical Market by Segment, 2010 

Companies Listed

AA Pharma
Abbott Laboratories
Able Labs
Abraxis Bioscience
Abrika Pharmaceuticals
Aceto Corporation
Actavis
Active Pharma
Adcock Ingram
Aegera Therapeutics
Alapis
Alcon
Alfred E. Tiefenbacher
Almirall Prodesfarma
Alnylam Pharmaceuticals
Alphapharm
Alpharma
Altra Investments
Amerigen Pharmaceuticals
AmerisourceBergen
Amgen
Amide Pharmaceutical
Amneal Pharmaceuticals
Amylin Pharmaceuticals
Anadys Pharmaceuticals
Ancraf
Andrx Corporation
Angelini
Angenerico
Apicore
ApoPharma
Apotex
APP Pharmaceuticals
Aprogen
aRigen Pharmaceuticals
Arrow Generics
Asahi Kasei Pharma Corporation
Ascent Pharmahealth
ASKA Pharmaceutical
Aspen Group
Aspen Pharma
Astellas
AstraZeneca
Aurobindo
AxiCorp Sapient Discovery
B. Braun Melsungen
Balkanpharma
Barr Pharmaceuticals
Baxter Healthcare
Baxter International
Bayer
Bayer Yakuhin
Bedford Laboratories
Beltapharm
Biddle Sawyer Corporation
Bilim Pharmaceuticals
Bioceuticals Arzneimittel
BioChimico
Biocon
Biogen Idec
biomo pharma
Bioniche Pharma
BioTech Pharma
BiotechCorp
Bioton
Biovail Laboratories
Biovena Pharma
Boehringer Ingelheim
Bristol-Myers Squibb
Bunker Industria Farmaceutica
Cadila Healthcare
Caraco Pharmaceutical Laboratories
Cardinal Health
CareFusion
Celgene Corporation
Celltrion
Center of Molecular Immunology (Cuba)
Cephalon
Chattem Chemicals
ChemGenex
Chon Kun Dang
Ciba-Geigy
CIMA Labs
Cipla
Claris Lifesciences
Clinton Foundation
Cobalt Laboratories
Colotech
Combino Pharm
CoPharma
Corporacion Infarmasa
Covidien
CSC Pharmaceuticals
CSFB Alternative Capital
CVS Pharmacy
Dabur Pharma
Daiichi Sankyo
Debiopharm
Delta Pharma
DepoMed
Dey Pharma
DoctorActive
Dr. Reddy's Laboratories
DuPont Crop Protection
DURECT Corporation
EastPharma
Ebewe Pharma
EBIK
Eden Biopharm
Egis Pharmaceuticals
Elan
Eli Lilly
Elpen Pharmaceutical
Elpharma
Emcure Pharmaceuticals
EMET Pharmaceuticals
EMS Sigma
Endo Pharmaceutical
Ethex Corporation
Eurodrug Laboratories
Eurofarma Laboratorios
European Central Bank
European Generic Medicines Association (EGA)
European Medicines Agency (EMEA/EMA)
Eximas
Fako Pharma
Faran Laboratories
Farmaprojects
Federal Court of Canada
Fidia farmaceutici
Filaxis
Fisiopharma
Food and Drug Administration (US FDA)
Fougera
Fournier
Fresenius Kabi
Fresenius Medical Care
Fuso Pharmaceutical Industries
G&W Laboratories
Galderma
Gedeon Richter
Genepharm Group
Genericon Pharma
Genéricos Españoles
Genertec Group
Genesoft
Genzyme
Germa Pharm
GlaxoSmithKline
Glenmark
Graceway Pharmaceuticals
Grindeks
Grünenthal
Grupo Azevedos
Gujarat Lyka Organics
Gyma
Health Canada
Helm Pharmaceuticals
Help
Helvepharm
Helvetia Pharma
Hexal
Hikma Pharmaceuticals
Hi-Tech Pharmacal
HLJ.Haerbin Phar
Hormosan Pharma
Hospira
HRA Pharma
Human Genome Sciences
Hungarian State Holding Company
Hypermarcas
Ibiopro Solutions
Impax Laboratories
Institut National de la Santé et de la Recherche Médicale (INSERM, France)
Institut Pasteur Korea
IntelliPharmaCeutics
International Monetary Fund
Invent Farma
IPR Pharmaceuticals
Italfarmaco
Itero Biopharmaceuticals
IVAX
Janssen
Javelin Pharmaceuticals
Johnson & Johnson
JS.L.Y.G. Hengr
JS Yangzijiang
Jubilant Life Science
Kendall
Kent Pharmaceuticals
Ke Lun Group
Kern Pharma
Kiadis Pharma
Kobrek Pharmaceuticals
Korea Research Institute of Bioscience and Biotechnology
Kowa Company
Krka
Kroger
KV Pharmaceuticals
Kyorin Pharmaceutical
Labesfal
Laboratoire Theramex
Laboratories Besins Iscovesco
Laboratorio Sanderson
Laboratorio Teuto Brasileiro
Laboratorios Cinf
Laboratorios Kendrick
LaborMed Pharma
Lamda Detergent
Lehigh Valley Technologies
LG Life Sciences
Lotos Laboratories
Lundbeck
Lupin
Madaus
Mallinckrodt
Masterleik
Matrix Laboratories
Mayne Pharma
McKesson Drug Company
Medco
Medeva Pharma
Medimpex
Medis
Medley
Medochemie
Meiji Seika Pharma
Menarini
Merck & Co.
Merck KGaA
Midlothian Laboratories
Millennium Pharmaceuticals
Milmet Labs
Mitani Sangyo
Mitsubishi Tanabe Pharma
MJ Pharma
MN Pharmaceuticals
Mochida Pharmaceutical
Moksha8 Pharmaceuticals
Momenta Pharmaceuticals
Multicare Pharmaceuticals
Mylan
Myrallis
Napp Pharmaceutical
Nellcor
neuraxpharm
Nichi-Iko Pharmaceutical Co.
Nihon Chouzai
Nippon Chemiphar
Nippon Kayaku
Nordic Capital
Normon
Novartis
Novel Laboratories
Novo Nordisk
Nycomed
Ohm Laboratories
Optimer Pharmaceuticals
Orchid Chemicals & Pharmaceuticals
Orion
Ortho-McNeil-Janssen
Paddock Laboratories
Pangeo
Par Pharmaceutical
Perlecan Pharma
Perrigo Company
Pfizer
Pharma Avalance
Pharma Dynamics
Pharmacia & Upjohn
PharmaPack International
Pharmascience
Pharmstandard
Phlox Pharma
Pinewood Laboratories
Piramal Healthcare Solutions
Pliva
Polfa Warszawa
Polifarma
Polpharma
Pozen
Pradeep Drug Company
Prazzi-Donaduzzi
Promius Pharma
Pronova BioPharma
ProStrakan
Purdue Pharma Products
Puritan-Bennett
Pymepharco
QRxPharma
Ranbaxy Laboratories
ratiopharm-Merckle Group
Rega Farma de Produtos
Remedica
Rheoscience
Rhodes Technologies
Ribbon
Richter-Helm Biologics
Rite Aid
Rivopharm
Robin Hood Holdings
Roche
Rohatyn Group
Ross Products
Safety Syringes
Safeway
Sagent Pharmaceuticals
Salomon Levin and Elstein
Samsung
Sandoz
Sanofi
Santarus
Sawai Pharmaceutical
Schering-Plough
Schwarz Pharma
Sekisui Medical
SeQuent Scientific
Servier
Shandong Luoxin PH
Shandong Ruiyang
Shandong Qilu
SH.Asia Pioneer PH
Shelys Pharmaceuticals
Shionogi Seiyaku Kabushki Kaisha
Sicor
Sindan
SK Chemicals
Solvay Pharmaceuticals
Somaxon Pharmaceuticals
Sovereign
Spear
Spirig Pharma
Stada Arzneimittel
Stiefel Research Australia
Streuli Pharma
Strides Arcolab
Sun Pharma
Synageva
Synthon Pharmaceutica
Syrrx
Taiyo
Takeda
Taro Pharmaceutical Industries
Teuto
Teva Pharmaceutical Industries
Teva-Kowa Pharma
Three Rivers
Tolmar
Towa Pharmaceutical
Triax Pharmaceuticals
Tris Pharma
UCB Manufacturing
Unimed Pharmaceuticals
United Nations (UN)
University of Aberdeen
University of Athens
University of Missouri
University of Thessaly
University of Tokyo
Valeant Pharmaceuticals
Valleylab
Velefarm
Veropharm
Versapharm
Veterin
Vianex
Vinchem
Walgreens
Walmart
Warner Chilcott
Watson Pharmaceuticals
West Ward
Winthrop
Wockhardt
World Health Organization (WHO)
Wyeth
Zentiva
Zhejiang Chiral Medicine Chemicals
Zhuhai Lizhu Group
ZiO Zdorovje
Zydus Cadila
Zydus Hospira Oncology 

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close